BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 25769073)

  • 1. Evaluation of Alemtuzumab Versus Basiliximab Induction: A Retrospective Cohort Study in Lung Transplant Recipients.
    Whited LK; Latran MJ; Hashmi ZA; Wang IW; Wozniak TC; Duncan MD; Roe DW; Baz MA; Hage CA
    Transplantation; 2015 Oct; 99(10):2190-5. PubMed ID: 25769073
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparison of three induction therapies on patients with delayed graft function after kidney transplantation.
    Umber A; Killackey M; Paramesh A; Liu Y; Qin H; Atiq M; Lee B; Alper AB; Simon E; Buell J; Zhang R
    J Nephrol; 2017 Apr; 30(2):289-295. PubMed ID: 27062485
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alemtuzumab induction in renal transplantation.
    Hanaway MJ; Woodle ES; Mulgaonkar S; Peddi VR; Kaufman DB; First MR; Croy R; Holman J;
    N Engl J Med; 2011 May; 364(20):1909-19. PubMed ID: 21591943
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Survival benefit of induction immunosuppression in cystic fibrosis lung transplant recipients.
    Kirkby S; Whitson BA; Wehr AM; Lehman AM; Higgins RS; Hayes D
    J Cyst Fibros; 2015 Jan; 14(1):104-10. PubMed ID: 24948447
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alemtuzumab induction and antibody-mediated kidney rejection after simultaneous pancreas-kidney transplantation.
    Pascual J; Pirsch JD; Odorico JS; Torrealba JR; Djamali A; Becker YT; Voss B; Leverson GE; Knechtle SJ; Sollinger HW; Samaniego-Picota MD
    Transplantation; 2009 Jan; 87(1):125-32. PubMed ID: 19136902
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five-year outcomes.
    Anil Kumar MS; Irfan Saeed M; Ranganna K; Malat G; Sustento-Reodica N; Kumar AM; Meyers WC
    Transpl Immunol; 2008 Nov; 20(1-2):32-42. PubMed ID: 18773960
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Timing of basiliximab induction and development of acute rejection in lung transplant patients.
    Swarup R; Allenspach LL; Nemeh HW; Stagner LD; Betensley AD
    J Heart Lung Transplant; 2011 Nov; 30(11):1228-35. PubMed ID: 21764603
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prospective randomized controlled trial of rabbit antithymocyte globulin compared with IL-2 receptor antagonist induction therapy in kidney transplantation.
    Pilch NA; Taber DJ; Moussa O; Thomas B; Denmark S; Meadows HB; McGillicuddy JW; Srinivas TR; Baliga PK; Chavin KD
    Ann Surg; 2014 May; 259(5):888-93. PubMed ID: 24513787
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Impact of Alemtuzumab and Basiliximab Induction on Patient Survival and Time to Bronchiolitis Obliterans Syndrome in Double Lung Transplantation Recipients.
    Furuya Y; Jayarajan SN; Taghavi S; Cordova FC; Patel N; Shiose A; Leotta E; Criner GJ; Guy TS; Wheatley GH; Kaiser LR; Toyoda Y
    Am J Transplant; 2016 Aug; 16(8):2334-41. PubMed ID: 26833657
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of Alemtuzumab Versus Basiliximab Induction Therapy in Elderly Kidney Transplant Recipients: A Single-Center Experience.
    Yakubu I; Ravichandran B; Sparkes T; Barth RN; Haririan A; Masters B
    J Pharm Pract; 2021 Apr; 34(2):199-206. PubMed ID: 31315501
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A retrospective comparison of the efficacy and safety in kidney transplant recipients with basiliximab and anti-thymocyte globulin.
    Wang W; Yin H; Li XB; Hu XP; Yang XY; Liu H; Ren L; Wang Y; Zhang XD
    Chin Med J (Engl); 2012 Mar; 125(6):1135-40. PubMed ID: 22613543
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pre-implantation basiliximab reduces incidence of early acute rejection in pediatric heart transplantation.
    Grundy N; Simmonds J; Dawkins H; Rees P; Aurora P; Burch M
    J Heart Lung Transplant; 2009 Dec; 28(12):1279-84. PubMed ID: 19864164
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alemtuzumab versus interleukin-2 receptor antibodies induction in living donor kidney transplantation.
    Sampaio MS; Kadiyala A; Gill J; Bunnapradist S
    Transplantation; 2009 Oct; 88(7):904-10. PubMed ID: 19935462
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early outcomes using alemtuzumab induction in lung transplantation.
    van Loenhout KC; Groves SC; Galazka M; Sherman B; Britt E; Garcia J; Griffith B; Iacono A
    Interact Cardiovasc Thorac Surg; 2010 Feb; 10(2):190-4. PubMed ID: 19939852
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Basiliximab versus rabbit anti-thymocyte globulin for induction therapy in patients after heart transplantation.
    Flaman F; Zieroth S; Rao V; Ross H; Delgado DH
    J Heart Lung Transplant; 2006 Nov; 25(11):1358-62. PubMed ID: 17097501
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparison of basiliximab and anti-thymocyte globulin as induction agents after lung transplantation.
    Hachem RR; Chakinala MM; Yusen RD; Lynch JP; Aloush AA; Patterson GA; Trulock EP
    J Heart Lung Transplant; 2005 Sep; 24(9):1320-6. PubMed ID: 16143251
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Maintenance immunosuppression with intermittent intravenous IL-2 receptor antibody therapy in renal transplant recipients.
    Gabardi S; Catella J; Martin ST; Perrone R; Chandraker A; Magee CC; McDevitt-Potter LM
    Ann Pharmacother; 2011 Sep; 45(9):e48. PubMed ID: 21811001
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quadruple immunosuppression with basiliximab, tacrolimus, mycophenolate mofetil and prednisone is safe and effective for renal transplantation.
    Miura M; Harada H; Fukuzawa N; Iwami D; Taniguchi A; Seki T; Togashi M; Ogawa Y; Satoh H; Hirano T
    Clin Transplant; 2005; 19 Suppl 14():54-8. PubMed ID: 15955170
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of single bolus ATG and Basiliximab as induction therapy in presensitized renal allograft recipients receiving tacrolimus-based immunosuppressive regimen.
    Yang SL; Wang D; Wu WZ; Lin WH; Xu TZ; Cai JQ; Tan JM
    Transpl Immunol; 2008 Jan; 18(3):281-5. PubMed ID: 18047938
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of induction immunosuppression on survival in heart transplant recipients: a contemporary analysis of agents.
    Whitson BA; Kilic A; Lehman A; Wehr A; Hasan A; Haas G; Hayes D; Sai-Sudhakar CB; Higgins RS
    Clin Transplant; 2015 Jan; 29(1):9-17. PubMed ID: 25284138
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.